Efforts to establish an international system for identifying and tracing drugs through the global supply chain are moving forward, despite multiple hurdles for regulators, manufacturers and distributors.
The Food and Drug Administration (FDA) recently announced that it would delay enforcement of requiring manufacturers to add product identifiers to drug packaging, a key step for establishing an interoperable drug tracking system by 2023 that will reduce drug diversion and the influx of counterfeit medicines into the United States.
These and other supply chain challenges will be discussed at a public meeting to be held Aug. 23, at FDA headquarters in Maryland, and at two additional meetings scheduled for Dec. 5–6, and Feb. 28, 2018.
To read the full original article, please click here.
